American Society of Hematology

Patients’ daily bleed diaries helped investigators understand why some bleeds are treated, and some are not, as well as their causes.

Jasmine Zain, MD, recaps the current and upcoming treatments in T-cell lymphoma and highlights the key clinical trials playing a role in the rare disease.

The pediatrician discusses key differences between treating pediatric and adult patients with hemophagocytic lymphohistiocytosis (HLH) with the recently FDA-approved emapalumab.

The therapy attempts to restore fetal hemoglobin production.

Ravulizumab dosed every 8 weeks was noninferior to eculizumab given every 2 weeks, but the treatment did not achieve superiority.

Among the highlights observed in the data, the single-agent oral demonstrated significant improvement in progression-free survival (PFS).

Full results from the phase 3 MURANO trial showed a reduced risk in disease progression and 87.9% overall survival in relapsed/refractory chronic lymphocytic leukemia patients treated with venetoclax/rituximab.

Currently available anemia therapies only provide benefit for about half of patients with a lower-risk myelodysplastic syndromes (MDS)-related condition—and about one-quarter of such patients dependent on red blood cell transfusions.

Justin Taylor, MD, explains new and unique data that show cases in which a solid tumor can become a hematologic malignancy, or leukemia.

Males with myeloproliferative neoplasms (MPN) were found to have inferior survival compared to females in a well-defined, prospective, observational cohort.

The odds ratio of patients on the therapy reaching ≥33% RBC transfusion burden reduction was 5 times greater than those on placebo.

Long-term data shows familial haploidentical stem cell transplantation (HISCT) improves quality of life and neurocognition in sickle cell disease patients.

Barbara Cappelli, MD, Eurocord International Registry, Paris, France, shared an overview from her team's study that found further evidence that for patients with severe sickle cell disease who have an HLA-identical sibling available as a donor, HSCT can be safe and effective.

Mitchell Smith, MD, Cleveland Clinic shared highlights of his team's posters and discussed the progression of immunotherapies at the 57th American Society of Hematology Annual Meeting.

A new treatment option for deep vein thrombosis (DVT) and pulmonary embolism (PE) was recently introduced, but it looks like old habits die hard when it comes to prescriptions.

Ventricular assist devices (VADs) are literally life savers for some patients with heart failure, however, the technology can be accompanied by serious risks.

Brian Bolwell, MD, Cleveland Clinic, discussed how all the information they're finding out about myeloid malignancies is very important, but also complex so making broad statements is challenging.

The phase three studies, B-LONG and Kids B-LONG, examined outcomes with a hemophilia B therapy in adults and adolescents. Now an extension study went further to verify the findings and the results were presented at the 57th American Society of Hematology Annual Meeting (ASH 2015) in Orlando, Florida.

Although the increased bleeding risk in patients with both acute and chronic liver disease is recognized, strategies to predict the occurrence are lacking. A team from South Korea discussed parameters to do just that during a poster session 57th American Society of Hematology Annual Meeting (ASH 2015) in Orlando, Florida.

At the 57th American Society of Hematology Annual Meeting, Christine Cserti-Gazdewich, BSc, MD, Blood Transfusion Laboratory, Toronto General Hospital discussed the progress made in blood unit storage.

Two studies have already shown that a hemophilia treatment option is safe and effective, but researchers from the United Kingdom took an in-depth look to confirm these outcomes.

Christine Cserti-Gazdewich, BSc, MD, Blood Transfusion Laboratory, Toronto General Hospital, and colleagues wanted to address the burgeoning concern that the longer blood units are stored, the likelier it may be to introduce harm or simply not work as well.

When a medical condition is paired with another, it could make for a trickier situation. New research found that some diseases can significantly impact platelet function while others appear to have no effect.

Seth Karol, MD, St. Jude's Children's Research Center and his team focused their research on the 10-20 age group, the "sweet spot" where the bones are still finishing up development and thus going to be susceptible to therapy.

New research further supports the understanding that patients with hemophilia suffer from pain and mobility issues, and it went on to uncover which joints are most greatly affected by the condition.

Seth Karol, MD, St. Jude's Children's Research Center discussed several ways in which he and his colleagues intensified therapy over the years and referred to a key toxicity that had emerged from the two drugs they used.

Bleeding events are to be expected in patients with primary immune thrombocytopenia (ITP), but the average time before the first episode may be sooner than you think.

Romiplostim has been indicated for adults with chronic immune thrombocytopenia (ITP), but what about for kids? A phase three study examined the notion during a presentation at the 57th American Society of Hematology Annual Meeting (ASH 2015) in Orlando, Florida.

Researchers assessed the effect of epoetin alfa biosimilar both with and without iron supplementation on CIA in patients undergoing treatment for oncologic and hematologic malignancies.

Analysis of study data from patients in real-world clinical setting showed a rapid increase in mean hemoglobin levels in this patient population, often as early as 3-4 weeks following initiation of treatment.